Loading...

Biotest

DB:BIO
Snowflake Description

Reasonable growth potential with imperfect balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
BIO
DB
€925M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. The last earnings update was 27 days ago. More info.


Add to Portfolio Compare Print
BIO Share Price and Events
7 Day Returns
0%
DB:BIO
-0.1%
DE Biotechs
1%
DE Market
1 Year Returns
-15.3%
DB:BIO
-7.4%
DE Biotechs
-5.6%
DE Market
BIO Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Biotest (BIO) 0% -0.8% 3% -15.3% 46.4% -18.4%
DE Biotechs -0.1% 6% -6.7% -7.4% 53.2% 11.6%
DE Market 1% 6.1% 8.4% -5.6% 10.9% 13.8%
1 Year Return vs Industry and Market
  • BIO underperformed the Biotechs industry which returned -7.4% over the past year.
  • BIO underperformed the Market in Germany which returned -5.6% over the past year.
Price Volatility
BIO
Industry
5yr Volatility vs Market

BIO Value

 Is Biotest undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Biotest. This is due to cash flow or dividend data being unavailable. The share price is €24.3.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Biotest's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Biotest's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:BIO PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in EUR €-0.33
DB:BIO3 Share Price ** DB (2019-04-24) in EUR €22.2
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.73x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.72x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Biotest.

DB:BIO PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= DB:BIO3 Share Price ÷ EPS (both in EUR)

= 22.2 ÷ -0.33

-68.1x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Biotest is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Biotest is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Biotest's expected growth come at a high price?
Raw Data
DB:BIO PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -68.1x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
56.4%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 269 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Biotest, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Biotest's assets?
Raw Data
DB:BIO PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in EUR €12.51
DB:BIO3 Share Price * DB (2019-04-24) in EUR €22.2
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.72x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
DB:BIO PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= DB:BIO3 Share Price ÷ Book Value per Share (both in EUR)

= 22.2 ÷ 12.51

1.77x

* Primary Listing of Biotest.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Biotest is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Biotest's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Biotest has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

BIO Future Performance

 How is Biotest expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
56.4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Biotest expected to grow at an attractive rate?
  • Biotest's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Biotest's earnings growth is expected to exceed the Germany market average.
  • Biotest's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:BIO Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:BIO Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 56.4%
DB:BIO Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 10.4%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.6%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:BIO Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:BIO Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 673 1
2022-12-31 561 1
2021-12-31 488 0 1
2020-12-31 448 -6 1
2019-12-31 422 -16 1
DB:BIO Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2018-12-31 400 -50 -13
2018-09-30 405 -16 18
2018-06-30 409 6 6
2018-03-31 400 15 1
2017-12-31 378 34 -16
2017-09-30 257 8 -48
2017-06-30 301 -8 -47
2017-03-31 340 35 -29
2016-12-31 408 66 6
2016-09-30 531 51 128
2016-06-30 525 57 52
2016-03-31 526 44 36

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Biotest's earnings are expected to grow significantly at over 20% yearly.
  • Biotest's revenue is expected to grow by 10.4% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:BIO Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Biotest Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:BIO Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 0.00 0.00 1.00
2020-12-31 -0.15 -0.15 -0.15 1.00
2019-12-31 -0.42 -0.42 -0.42 1.00
DB:BIO Past Financials Data
Date (Data in EUR Millions) EPS *
2018-12-31 -0.33
2018-09-30 0.45
2018-06-30 0.14
2018-03-31 0.01
2017-12-31 -0.41
2017-09-30 -1.31
2017-06-30 -1.22
2017-03-31 -0.73
2016-12-31 0.15
2016-09-30 3.08
2016-06-30 1.37
2016-03-31 0.92

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Biotest is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Biotest's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Biotest has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

BIO Past Performance

  How has Biotest performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Biotest's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Biotest does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Biotest's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Biotest's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Biotest's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Biotest Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:BIO Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 400.30 -12.90 84.70 48.50
2018-09-30 404.70 18.00 90.90 49.80
2018-06-30 408.70 5.80 91.40 51.60
2018-03-31 400.40 0.50 99.20 54.40
2017-12-31 378.10 -16.40 100.30 55.40
2017-09-30 257.20 -48.30 95.10 56.20
2017-06-30 300.50 -47.00 92.80 51.60
2017-03-31 340.10 -29.30 89.30 48.70
2016-12-31 408.00 6.00 87.80 48.30
2016-09-30 530.50 128.30 78.10 35.50
2016-06-30 524.50 52.00 87.90 61.70
2016-03-31 525.70 35.90 87.90 72.40
2015-12-31 534.60 27.00 93.40 78.50
2015-09-30 590.00 -88.10 107.40 92.80
2015-06-30 605.60 3.20 108.90 72.90
2015-03-31 602.30 15.60 109.60 68.60
2014-12-31 582.00 19.20 107.80 67.20
2014-09-30 543.20 27.30 105.30 71.50
2014-06-30 521.60 30.50 97.90 68.70
2014-03-31 504.30 30.00 95.00 67.30
2013-12-31 500.80 32.00 92.50 64.60
2013-09-30 482.60 31.50 93.70 57.70
2013-06-30 463.10 28.50 92.40 55.10
2013-03-31 451.00 26.30 89.10 51.40
2012-12-31 440.00 23.10 87.30 51.40
2012-09-30 435.03 19.72 84.30 51.11
2012-06-30 429.33 17.72 82.40 53.21

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Biotest has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Biotest has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Biotest improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Biotest's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Biotest has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

BIO Health

 How is Biotest's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Biotest's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Biotest is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Biotest's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Biotest's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 1.5x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Biotest Company Filings, last reported 3 months ago.

DB:BIO Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 495.20 329.40 77.10
2018-09-30 505.30 353.10 156.40
2018-06-30 499.00 615.50 461.00
2018-03-31 340.10 471.30 171.60
2017-12-31 347.80 406.40 22.90
2017-09-30 331.40 412.40 32.00
2017-06-30 339.50 414.30 64.40
2017-03-31 335.90 350.50 48.90
2016-12-31 360.70 346.20 84.20
2016-09-30 407.00 347.80 130.00
2016-06-30 416.70 349.60 166.20
2016-03-31 410.10 349.20 171.00
2015-12-31 412.30 344.60 154.10
2015-09-30 398.20 347.20 88.30
2015-06-30 484.00 348.40 96.80
2015-03-31 502.90 344.40 125.00
2014-12-31 480.20 331.90 234.10
2014-09-30 486.80 249.10 79.50
2014-06-30 468.10 246.70 89.80
2014-03-31 465.70 246.10 174.20
2013-12-31 460.70 231.50 204.40
2013-09-30 456.30 98.10 70.70
2013-06-30 452.80 102.60 97.30
2013-03-31 378.60 103.20 32.30
2012-12-31 369.40 112.50 57.20
2012-09-30 357.40 134.10 55.50
2012-06-30 353.90 135.90 58.90
  • Biotest's level of debt (66.5%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (50.3% vs 66.5% today).
  • Operating cash flow is negative therefore debt is not well covered.
  • Biotest is making a loss, therefore interest payments are not well covered by earnings.
X
Financial health checks
We assess Biotest's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Biotest has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

BIO Dividends

 What is Biotest's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0.18%
Current annual income from Biotest dividends. Estimated to be 0.18% next year.
If you bought €2,000 of Biotest shares you are expected to receive €4 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Biotest's pays a lower dividend yield than the bottom 25% of dividend payers in Germany (1.44%).
  • Biotest's dividend is below the markets top 25% of dividend payers in Germany (3.7%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:BIO Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:BIO Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.04 1.00
2020-12-31 0.04 1.00
2019-12-31 0.04 1.00
DB:BIO Past Annualized Dividends Data
Date (Data in €) Dividend per share (annual) Avg. Yield (%)
2019-03-28 0.040 0.182
2018-03-23 0.040 0.169
2017-03-30 0.070 0.322
2016-03-23 0.040 0.279
2015-05-07 0.220 1.301
2014-05-07 0.210 0.705
2013-05-08 0.187 0.841
2012-03-22 0.167 1.131
2012-01-16 0.167 1.284
2011-03-17 0.147 1.080
2010-03-01 0.133 1.106

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Biotest is not paying a notable dividend for Germany, therefore no need to check if the payments are stable.
  • Biotest is not paying a notable dividend for Germany, therefore no need to check if the payments are increasing.
Current Payout to shareholders
What portion of Biotest's earnings are paid to the shareholders as a dividend.
  • No need to calculate the sustainability of Biotest's dividends as it is not paying a notable one for Germany.
Future Payout to shareholders
  • No need to calculate the sustainability of Biotest's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Biotest's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Biotest afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Biotest has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

BIO Management

 What is the CEO of Biotest's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Bernhard R. Ehmer
COMPENSATION €1,177,000
AGE 63
TENURE AS CEO 4.3 years
CEO Bio

Dr. Bernhard R. M. Ehmer, M.D., has been the Chief Executive Officer and Chairman of the Board of Management at Biotest AG since January 1, 2015 and its Member of the Board of Management since November 1, 2014. Dr. Ehmer has been Chairman of the Board at Symphogen A/S since September 2018. Dr. Ehmer served as the President of ImClone Systems Incorporated. He served as a Managing Director of International Operations and Senior Vice President at Imclone Systems Inc., since May 30, 2008. He served as Member of the Management Board at Hybrigenics Société Anonyme since August 2, 2006. Dr. Ehmer served as a Vice President of Business Area Oncology at Merck Electronic Chemicals Holding Gmbh since 2000 and Head of its Corporate Strategic Planning and Alliance Management - Ethicals Division since November 2005. He served as the President and Chief Executive Officer of Fresenius Biotech GmbH from April 2007 to May 2008. Previously, he served as Chief Executive Officer and Managing Director of Biopheresis Technologies from May 2006 to April 2007. He worked with KGaA for eight years. Dr. Ehmer joined Merck in 1998 as its Vice President of Clinical Research and Development Operations. He joined Boehringer Mannheim, where he held various positions in its pharmaceuticals sector, including Research and Development, Global Marketing and Regional Management. Dr. Ehmer served as a Member of Management Board of Société Anonyme since August 2, 2006. He served as a Director at ADMA Biologics, Inc. since June 2017 Until February 15, 2018. He has been Member of Supervisory Board at Affimed N.V. since January 21, 2016. Dr. Ehmer served as Non-Executive Independent Director of Hybrigenics SA since August 2, 2006. He served as a Director of BioPheresis Technologies Inc. He is the author or co-author of approximately 60 scientific publications. He holds a Medical Degree from University of Munich and Heidelberg. He completed his residency in Internal Medicine at the Academic Teaching Hospital at the University in 1986.

CEO Compensation
  • Bernhard R.'s compensation has increased whilst company is loss making.
  • Bernhard R.'s remuneration is about average for companies of similar size in Germany.
Management Team Tenure

Average tenure of the Biotest management team in years:

4.3
Average Tenure
  • The tenure for the Biotest management team is about average.
Management Team

Bernhard R. Ehmer

TITLE
Chairman of the Board of Management & CEO
COMPENSATION
€1M
AGE
63
TENURE
4.3 yrs

Michael Ramroth

TITLE
CFO, Head of Finances & Central Services and Member of the Board of Management
COMPENSATION
€1M

Georg Floß

TITLE
COO & Member of the Board of Management
COMPENSATION
€999K
TENURE
6.3 yrs

Monika Buttkereit

TITLE
Head of Investor Relations

Christina Erb

TITLE
Head of Corporate HR
TENURE
3.7 yrs

Katrin Bernöster

TITLE
Head of the Project Management Organisation

Peter Seith

TITLE
Head of Quality Operations

Jörg Schüttrumpf

TITLE
Head of Research & Development

Wolfgang Möller

TITLE
Head of Development - Plasma Protein

Hermann Keuper

TITLE
Senior Vice President of Manufacturing
Board of Directors Tenure

Average tenure of the Biotest board of directors in years:

7.7
Average Tenure
  • The tenure for the Biotest board of directors is about average.
Board of Directors

Rolf Hoffmann

TITLE
Chairman of the Supervisory Board
AGE
59

Tan Yang

TITLE
Deputy Chairman of Supervisory Board

Cathrin Schleussner

TITLE
Member of the Supervisory Board
TENURE
7.8 yrs

Christine Kreidl

TITLE
Supervisory Board member
TENURE
1.7 yrs

Kerstin Birkhahn

TITLE
Member of Supervisory Board
TENURE
9 yrs

Jurgen Heilmann

TITLE
Member of Supervisory Board
TENURE
7.6 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Biotest's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Biotest has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

BIO News

Simply Wall St News

BIO Company Info

Description

Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in haematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin for the treatment of haemophilia A acute therapy and prophylaxis; Haemonine for haemophilia B acute therapy and prophylaxis; Indatuximab Ravtansine (BT-062) for multiple myeloma and solid tumors; and Vihuma for treating haemophilia A acute therapy and prophylaxis. The company’s products also comprise Cytotect for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in newborns; Hepatect for prophylaxis of hepatitis B re-infection; Intratect for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, as well as neurological indications; IgG Next Genration for primary immune deficiency and immunothrombocytopenia; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. In addition, it provides Albiomin for the treatment of blood volume depletion; Biseko to treat volume and serum protein depletion; Cofact for the treatment of clotting factors deficiency; Fibrinogen to treat congenital and acquired fibrinogen deficiency; Trimodulin for the community-acquired pneumonia; and Pentaglobin to treat bacterial infections. The company’s products under development include BT-063 for the treatment of systemic lupus erythematosus; BT-094 (Cytotect 70) to treat cytomegalovirus infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. Biotest Aktiengesellschaft was founded in 1946 and is headquartered in Dreieich, Germany. Biotest Aktiengesellschaft is a subsidiary of Tiancheng International Investment Limited.

Details
Name: Biotest Aktiengesellschaft
BIO
Exchange: DB
Founded: 1946
€924,982,690
39,571,452
Website: http://www.biotest.com
Address: Biotest Aktiengesellschaft
Landsteinerstrasse 5,
Dreieich,
63303,
Germany
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
DB BIO3 Preference Shares Deutsche Boerse AG DE EUR 06. Jan 1992
OTCPK BIES.F Preference Shares Pink Sheets LLC US USD 06. Jan 1992
XTRA BIO3 Preference Shares XETRA Trading Platform DE EUR 06. Jan 1992
LSE 0N70 Preference Shares London Stock Exchange GB EUR 06. Jan 1992
SWX BIO3 Preference Shares SIX Swiss Exchange CH CHF 06. Jan 1992
WBAG BIO3 Preference Shares Wiener Boerse AG AT EUR 06. Jan 1992
BATS-CHIXE BIO3D Preference Shares BATS 'Chi-X Europe' GB EUR 06. Jan 1992
XTRA BIO Ordinary Shares XETRA Trading Platform DE EUR 03. Jun 1996
DB BIO Ordinary Shares Deutsche Boerse AG DE EUR 03. Jun 1996
LSE 0N6Z Ordinary Shares London Stock Exchange GB EUR 03. Jun 1996
LSE 0RQ5 PRF NPV (ASD 15/06/17 TIANCHENG CASH) London Stock Exchange GB EUR 23. May 2017
LSE 0RQ4 NPV (ASD 15/06/2017 TIANCHENG CSH) London Stock Exchange GB EUR 23. May 2017
BATS-CHIXE BIOD Ordinary Shares BATS 'Chi-X Europe' GB EUR 03. Jun 1996
Number of employees
Current staff
Staff numbers
1,663
Biotest employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/24 20:48
End of day share price update: 2019/04/24 00:00
Last estimates confirmation: 2019/03/29
Last earnings filing: 2019/03/28
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.